Heart failure, a common heart disease affecting nearly 6 million Americans, is associated
with high rates of hospitalization and death. Abnormalities in the autonomic nervous system
are thought to play an important role in the progression of heart failure. This proposal aims
to determine whether novel application of pyridostigmine, a drug currently approved by the
FDA only for the treatment of neuromuscular disease, can improve autonomic nervous system
function in heart failure patients.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Nathan Kline Institute for Psychiatric Research National Heart, Lung, and Blood Institute (NHLBI) Oklahoma State University